In an attempt to reduce or eliminate homologous red blood cell transfusion requirements during allogeneic bone marrow transplantation (BMTI, we instituted a novel program whereby recombinant human erythropoietin was administered to pairs of BMT donors and recipients. Eleven recipients and their HLA-matched donors were enrolled. Donors treated with recombinant human erythropoietin (rHuEPO) were phlebotomized a median of 6 U (range, 4 to 11 U) of blood over a 5-week period. This donor-derived blood was available to the BMT donor or recipient as needed. Transplant recipients were also treated with rHuEPO post-BMT to RYTHROPOIETIN (EPO) is a glycoprotein hormone crucial to the regulation of erythropoiesis.' Produced by the kidney and, to a lesser extent, by the liver in response to hypoxia, EPO binds to receptors on erythroid progenitors, thereby stimulating red blood cell (RBC) production.' The successful cloning of the EPO has allowed synthesis of pharmacologic quantities of the hormone and the subsequent introduction of recombinant human EPO (rHuEPO) into clinical use. rHuEPO has been shown to ameliorate certain anemias associated with low endogenous EPO levels and has been used to stimulate erythropoiesis in the presurgical setting, thus facilitating autologous blood Allogeneic bone marrow transplantation (BMT) is being performed with increasing frequency and remains the only curative treatment modality for certain diseases such as chronic myelogenous leukemia (CML). Transfusion requirements in BMT are significant and are associated with untoward effects, including febrile transfusion reactions, allosensitization, and transmission of infection. In addition, blood products are in short supply and are expensive.
hasten erythropoiesis. Five of 11 BMT recipients underwent transplant receiving only donor-derived red blood cell transfusions, compared with 0 of 11 concomitant control recipients (P = .04). In addition, the time to absolute reticulocyte count alO'lpL was statistically shorter in the rHuEPOtreated recipient group. This study serves as a paradigm for hematopoietic growth factor use in allogeneic BMT to decrease or eliminate homologous transfusion exposures and to possibly hasten hematopoietic engraftment.
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prospective study to determine the safety and efficacy of rHuEPO administration to pairs of BMT donors and their recipients. The strategy we used exploited the fact that BMT donor blood becomes autologous to the recipient's graft by virtue of the transplant. rHuEPO was administered to the BMT donors to facilitate blood donation, thus providing donor-derived RBCs to the HLA-matched recipient. These units were also available to be reinfused into the donor, if required, after BM harvest. In addition, rHuEPO was administered to the BMT recipients immediately after transplant to counteract the anticipated low endogenous EPO state. der. Control subject data were available from a concomitant cohort of 11 allogeneic BMT donors and recipients who were not ABH compatible or who did not participate in the study. rHuEPO-treated donors and recipients and control recipient characteristics are summarized in Table 1 .
MATERIALS AND METHODS

Patients. Eleven adult patients (age >
Study protocol. The study protocol is shown in Fig 1. BM donors received oral iron supplementation (Niferex-150 twice daily providing 300 mg elemental irodday) and rHuEPO (F'rocrit; Ortho Biotech, Inc. Raritan, NJ) at 300 U k g subcutaneously 5 dayslweek beginning 3 weeks before BM harvest and continuing for 2 weeks afterward for a total of 25 doses. The donors were instructed to self-inject rHuEPO or have it administered by a family member or nurse. One unit of RBCs was obtained on the first day of the study and twice weekly thereafter, provided that the hematocrit (Hct) was 233%, consistent with the American Association of Blood Banks guidelines for autologous donation. The collected blood was available to the donor after the BM harvest if required, or it was allocated to the recipient. If the BMT date was unavoidably postponed (2 patients), rHuEPO therapy was interrupted and resumed the week preceding the harvest. This was done to ensure that no patient received greater than 5 weeks of rHuEPO treatment and to allow its administration for 1 week immediately before the harvest to stimulate erythropoiesis in the allograft. Transplant recipients received rHuEPO at 200 Uikg as an intravenous (IV) bolus daily for 28 days, commencing on day + 1 of the transplant, the day after marrow infusion. Neither rHuEPO-treated recipients nor control recipients received oral iron supplementation because of concerns regarding potential gastrointestinal side effects that might exacerbate toxicity associated with the preparative regimens. Ten milliliters of donor BM was collected per kilogram of recipient body mass and infused into each recipient.
Complete blood counts and reticulocyte counts were obtained at least thrice weekly on the study and control recipients. Reticulocyte number was determined by flow cytometry using thiazole orange." Renal and liver function was monitored a minimum of three times per week and iron, total iron binding capacity (TIBC), ferritin, folate, and vitamin BI2 levels were obtained upon entry into the study. The number of RBC and platelet transfusions was recorded for both donors and recipients. Blood obtained from the donor is referred to as donor-derived; for purposes of this study, blood obtained from any source other than the donor is referred to as homologous. Transfusions were administered at the discretion of the attending physicians and house staff. All transfusions were routinely irradiated post-BMT.
BMT preparative regimen and graft-versus-host disease (GVHD)
prophylaxis. BMT recipients were treated with one of three preparative regimens: Busulfan at 1 mg/kg every 6 hours on days -9 to -6 and cyclophosphamide at 1,500 mg/m21d on days -5 to -2; Cytoxan at 1,800 mg/m21d on days -5 to -4 and total body irradiation (TBI) at 175 cGy twice daily on days -3 to 0; or Ara-C 3 g/ m2 every 12 hours on days -7 to -5, cyclophosphamide at 1,800 mg/m2 on days -3 and -2, and TB1 at 175 cGy twice daily on days -3 to 0. All patients received GVHD prophylaxis consisting of methotrexate at 15 mglm' on day 1, and at 10 mg/m* on days 3, 6, and 11 and Cyclosporine at 1 .S mgkg twice daily beginning 1 day before marrow infusion.
This study was approved by the Human Research Committee of the Brigham and Women's Hospital and informed consent was obtained from each study participant before beginning the study.
Statistical analyses. Cumulative probability was determined for the time to absolute reticulocyte count of > l @ cells/pL, absolute neutrophil count of z500lpL, and freedom from platelet transfusion (defined as the day after the last platelet transfusion). The Student's t-test, Fisher's exact test, and log-rank test were used to compare differences. All comparisons are two-tailed. Table 2 . rHuEPO was generally well tolerated. However, two donors withdrew from the study after receiving 15 of 25 (donor no. 1) and 19 of 25 (donor no. 6 ) doses of rHuEPO, respectively, citing the inconvenience and discomfort associated with the multiple injections. These BMT donors had already been phlebotomized 5 U (donor no. 1) and 6 U (donor no. 6 ) of blood. From the entire group of l 1 rHuEPO-treated donors, a median of 6 U of RBCs (range, 4 to 1 l U) was obtained over the 5-week period. One BMT donor (no. 2) with a very brisk erythropoietic response was allowed to donate an 1 1 th U of blood. Five of the 1 1 treated donors received autologous transfusion of 1 or 2 U of RBCs after BM harvest. Seven of 11 control donors electively provided autologous blood (l to 2 U) before BM harvest; 5 of these were transfused with 1 to 2 U. As shown in Table 1 , several of the female BMT donors had diminished iron stores. Despite rHuEPO therapy, these donors were unable to donate as many units of blood as donors with greater iron stores; nonetheless, all donors were phlebotomized a minimum of 4 U of blood.
RESULTS
Donor results. Donor results are shown in
Interestingly, although equal volumes of BM were collected from both rHuEPO-treated and control BMT donors, the mean number of mononuclear cells obtained was greater Table   3 . Five of 11 transplant recipients in the rHuEPO-treated group received only donor-derived RBC transfusions while on study, compared with 0 of 11 in the control group ( P = .04). One additional patient inadvertently received 1 U of non-donor-derived blood although donor-derived blood was available. Therefore, 6 of 1 1 patients had sufficient donorderived blood available so that all homologous RBC transfusions could have been avoided. The 5 BMT patients who were exposed only to donor-derived RBCs were transplanted for stable-phase CML (n = 31, Hodgkin's disease (n = I), and non-Hodgkin's lymphoma (n = 1). During the study period, these patients received a median of 3 (range, 1 to 15) bags of single donor platelets. The mean total number of RBC transfusions required by the rHuEPO-treated BMT recipients during the 28-day study period was 8.3 ? 6.9, compared with 8.1 If: 5. 6 in the 11 controls. However, if one considers only homologous transfusions, the rHuEPO patients received a mean of 4.5 2 6.2 U of RBCs (.OS < P < .l) ( Table 4 ). The mean Hct for the two groups was comparable during the entire study period (data not shown), suggesting that, although the attending physicians may have been aware of this study, it did not unduly influence transfusion decisions. After the 28-day study period, 3 of 11 rHuEPO-treated patients required additional RBC transfusions, compared with 6 of 11 control patients (P = .04). Although the numbers are small, it appears that patients requiring more transfusions tended to have more severe hemorrhagic complications; the numbers are too small to accurately assess whether the onset and degree of reticulocytosis was significantly correlated with transfusion requirements. In addition, the populations are too small to adequately assess the impact of the preparative regimens on For personal use only. on October 3, 2017. by guest www.bloodjournal.org From The absolute reticulocyte counts for the study and control BMT recipients are depicted in Fig 2. The time to absolute reticulocyte count of 2 lo4 cells/pL was statistically shorter in the rHuEPO-treated group compared with that of the control patients (P = .03). There was no significant difference in the time to absolute neutrophil count of 2500/pL and platelet transfusion independence in the rHuEPO-treated group versus those in the control group. The mean number of platelet transfusions during the 28-day period for the rHuEPO-treated and control recipients was 17 ? 16 versus 11 2 8 (P = .27).
No control patient died during the 28-day study period; one rHuEPO-treated patient expired on day 28.
Subsequently, 5 study recipients and 2 control recipients died of transplant-related toxicity.
DISCUSSION
Allogeneic BMT affords a unique setting for the administration of rHuEPO. After BMT, endogenous serum EPO levels have been shown to peak on about day 7 and then decrease to inappropriately low levels for the degree of anemia present.'"* This finding has prompted several investigators to administer rHuEPO to allograft recipients. Vannucchi et all4 administered rHuEPO at 50 Ukg IV thrice daily to 8 patients after BMT on days l through 30. RBC transfusion requirements before and after day 30 and the time to transfusion independence were decreased in the treated patients compared with 13 controls. In addition, in the rHuEPOtreated group, reticulocyte number was higher at day 21, as was the maximum reticulocyte count during the study period. Steegmann et all5 administered rHuEPO to 13 allogeneic BMT recipients at a dose of 100 Ukg IV bolus on days 0 through 7 and 150 Ukg IV bolus on days 7 through 30.
In this prospective, controlled, randomized study, decreased 1955 RBC transfusion requirement and earlier reticulocytosis were again noted in the rHuEPO-treated recipients. In addition, the number of platelet transfusions and time to platelet transfusion independence were reduced. Despite these positive findings, all BM recipients required homologous RBC transfusions.
Exposure of the BMT recipient to homologous RBCs might be totally eliminated if, in addition to rHuEPO administration, donor-derived blood was available for transfusion. Goodnough et ala demonstrated that patients scheduled to undergo elective orthopedic surgery were able to donate significantly more autologous blood when receiving rHuEPO compared with a placebo control group. BMT recipients are unable to donate blood because many are anemic before transplant. However, donor blood becomes autologous to the recipient's graft by virtue of the transplant procedure. Consequently, administering rHuEPO to BMT donors is a novel way of providing donor-derived RBCs to the BMT recipient.
In this study, administration of rHuEP0 to pairs of BMT donors and recipients was safe and effective. rHuEPO did not seem to retard or enhance nonerythropoietic reconstitution of marrow, as judged by the recovery of an absolute neutrophil count of 2500/pL and day to platelet transfusion independence. BMT donors were particularly motivated to provide "safe" blood products for their matched recipient and most individuals found it a rewarding experience. Remarkably, nearly half of rHuEPO-treated BMT recipients received only donor-derived RBCs during the 28-day study period after BMT. This is an extremely rare Occurrence in patients undergoing BMT without rHuEPO.
It is important to note that the 6 patients who benefited most from this protocol received transplants as treatment for chronic-phase CML, Hodgkin's disease, and non-Hodgkin's lymphoma (Table 3) . These patients had minimal transfusion exposures before transplantation. Therefore, eliminating homologous RBC exposure in this group of transfusion naive individuals may be particularly worthwhile. However, these For personal use only. on October 3, 2017. by guest www.bloodjournal.org From patients still required homologous platelet transfusions. Before widespread acceptance of a protocol similar to the one used in this study, strategies must be available to limit not only exposure to homologous RBCs but also exposure to homologous platelets. Platelet transfusions pose a difficult problem because, in addition to the infectious risks, alloimmunization is frequently encountered. Because rHuEPO ameliorates anemia in BMT donors, often a limiting factor in allowing platelet pheresis of BMT donors, future protocols can be designed to decrease RBC donations by the donor and substitute them with platelet donations, thereby potentially completely eliminating homologous blood exposure to the BMT recipient. In addition, as platelet storage techniques improve andor megakaryocyte growth factors are discovered, they may be combined with the procedures used in this study protocol to increase the chances of totally eliminating homologous blood exposure in many recipients of allogeneic BMT.
The ability to successfully donate large quantities of blood in a short period of time depends largely on both total body mass and total body iron stores.*.l6 This was also true in this study, as can be inferred from Tables 1 and 2 . Women had less substantial iron stores than men and, generally, were unable to donate as many units of RBCs. In fact, several of the BMT donors were relatively iron deficient. Although they were still able to all donate at least 4 U of blood, their erythropoietic response was clearly compromised, despite aggressive oral iron supplementation. It is becoming increasingly clear that if one pharmacologically stimulates erythropoiesis with rHuEP0, iron availability may quickly become rate-limiting, even in individuals receiving oral iron supplementati~n.'~ Future studies may consider the use of parenteral iron supplementation (in BMT donors and/or recipients) to enhance the erythropoietic response in individuals with modest iron stores, although this must be weighed against the potential of an anaphylactic response to such agents.
In addition to decreasing homologous RBC exposure, rHuEPO-treated BMT recipients demonstrated a more rapid increase in reticulocyte number compared with controls. This effect may be mediated directly by administration of rHuEPO to the recipient, as has been suggested by previous s t~d i e s ,~~*~~ but may also reflect an allogeneic BMT graft primed for erythropoiesis through donor exposure to rHuEP0. To properly answer this question would require larger studies and additional arms in which rHuEPO is administered only to the BMT donor or the BMT recipient but not to both in the same donorhecipient pair.
This study represents a pilot feasibility investigation. The number of subjects was small and the control BMT recipients were not entirely comparable to the rHuEPO-treated recipients in disease and ABH compatibility (Table 1) . Future studies will need to further explore not only strategies for decreasing homologous platelet transfusions, as noted above, but must also address issues of cost-effectiveness. The present study was not designed to do so. Factors that will significantly impact on such a cost analysis include not only the cost of rHuEPO (a factor that is likely to change over time), but also the total dose of rHuEPO that is required and savings that might be accrued by decreasing infectious complications and bleeding complications (if donor-derived platelets can be procured as outlined above). Nonetheless, the data obtained from this pilot study are encouraging and this study may serve as a model on which to base future investigations into the use of hematopoietic growth factors in the allogeneic BMT setting. For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
